Babesia Microti, Babesia Microti Dna, Borrelia Burgdorferi Nosode, Borrelia Burgdorferi Dna

Generic Name: babesia microti, babesia microti dna, borrelia burgdorferi nosode, borrelia burgdorferi dna

Over-the-Counter (OTC)

Dosage form: LIQUID. Active ingredients: BABESIA MICROTI (30 [hp_X]/mL); BABESIA MICROTI DNA (30 [hp_X]/mL); BORRELIA BURGDORFERI (30 [hp_X]/mL); BORRELIA BURGDORFERI DNA (30 [hp_X]/mL). Category: DRUG FOR FURTHER PROCESSING.

Overview

Dosage form: LIQUID. Active ingredients: BABESIA MICROTI (30 [hp_X]/mL); BABESIA MICROTI DNA (30 [hp_X]/mL); BORRELIA BURGDORFERI (30 [hp_X]/mL); BORRELIA BURGDORFERI DNA (30 [hp_X]/mL). Category: DRUG FOR FURTHER PROCESSING.

Dosage

Available as liquid.

Related Medications

Gadoterate Meglumine

gadoterate meglumine

11 DESCRIPTION Gadoterate Meglumine Injection, USP is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-,[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceto(4-)-.kappa.N1, .kappa.N4, .kappa.N7, .kappa.N10, .kappa.O1, .kappa.O4, .kappa.O7, .kappa.O10]gadolinate(1-)(1:1); it has a formula weight of 753.9 g/mol and empirical formula of C 23 H 42 O 13 N 5 Gd (anhydrous basis).

Ravulizumab

ravulizumab

Complement Inhibitor [EPC]

11 DESCRIPTION Ravulizumab-cwvz, a complement inhibitor, is a humanized monoclonal antibody (mAb) produced in Chinese hamster ovary (CHO) cells. Ravulizumab-cwvz consists of 2 identical 448 amino acid heavy chains and 2 identical 214 amino acid light chains and has a molecular weight of approximately 148 kDa. The constant regions of ravulizumab-cwvz include the human kappa light chain constant region, and the protein engineered "IgG2/4" heavy chain constant region.

Ranibizumab-eqrn

ranibizumab-eqrn

Vascular Endothelial Growth Factor Inhibitor [EPC]

11 DESCRIPTION Ranibizumab-eqrn is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-eqrn binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab-eqrn, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system.

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.